selurampanel selurampanel selurampanel (inn, code name bgg492) is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the ampa and kainate receptors and, as of 2015, is being investigated in clinical trials by novartis for the treatment of epilepsy. it has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects. selurampanelclinical dataatc codenoneidentifiers iupac name n-methanesulfonamide cas number912574-69-7pubchem cid45381907chemspider32698379unii7wg1mr7darcomptox dashboard (epa)dtxsid00238467 chemical and physical dataformulac16h19n5o4smolar mass377.42 g·mol−13d model (jsmol)interactive image smiles cc(c)c1cc2c(cc1c3ccnn3c)c(=o)n(c(=o)2)ns(=o)(=o)c inchi inchi=1s/c16h19n5o4s/c1-9(2)10-8-13-12(7-11(10)14-5-6-17-20(14)3)15(22)21(16(23)18-13)19-26(4,24)25/h5-9,19h,1-4h3,(h,18,23)key:mcecsffxupepdb-uhfffaoysa-n